{"id":"NCT00896337","sponsor":"Boston Scientific Corporation","briefTitle":"EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries","officialTitle":"A Boston Scientific Trial of the EPIC™ Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05","primaryCompletion":"2011-09","completion":"2013-12","firstPosted":"2009-05-11","resultsPosted":"2012-07-03","lastUpdate":"2015-05-07"},"enrollment":125,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Iliac Artery Stenosis"],"interventions":[{"type":"DEVICE","name":"Epic™ Nitinol Stent System","otherNames":[]},{"type":"DRUG","name":"Anti-platelet therapy","otherNames":[]},{"type":"DRUG","name":"Anti-coagulation therapy","otherNames":[]}],"arms":[{"label":"ORION","type":"EXPERIMENTAL"}],"summary":"The ORION study is being conducted to determine whether the Epic™ Nitinol Stent for primary stenting of iliac atherosclerotic lesions shows acceptable performance at 9 months.","primaryOutcome":{"measure":"Device- and/or Procedure-related Major Adverse Events (MAE)","timeFrame":"9 Months","effectByArm":[{"arm":"Epic Stent","deltaMin":3.4,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":21},"locations":{"siteCount":28,"countries":["United States"]},"refs":{"pmids":["24754280"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":77,"n":125},"commonTop":["Pain In Extremity","Back Pain","Catheter Site Haematoma","Arthralgia","Angina Pectoris"]}}